D. Scott Neal buys $194,798 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : D. Scott Neal scooped up 12 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 1,768 shares of Johnson & Johnson which is valued at $194,798.Johnson & Johnson makes up approximately 0.18% of D. Scott Neal’s portfolio.

Johnson & Johnson opened for trading at $110 and hit $111.1 on the upside on Monday, eventually ending the session at $110.93, with a gain of 0.68% or 0.75 points. The heightened volatility saw the trading volume jump to 77,72,549 shares. Company has a market cap of $306,096 M.

Other Hedge Funds, Including , Swarthmore Group Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 6,100 additional shares and now holds a total of 22,725 shares of Johnson & Johnson which is valued at $2,503,841. Johnson & Johnson makes up approx 0.38% of Swarthmore Group Inc’s portfolio.Hexavest reduced its stake in JNJ by selling 10,631 shares or 0.66% in the most recent quarter. The Hedge Fund company now holds 1,610,619 shares of JNJ which is valued at $177,458,001. Johnson & Johnson makes up approx 2.74% of Hexavest’s portfolio.E&g Advisors Lp reduced its stake in JNJ by selling 3,500 shares or 29.59% in the most recent quarter. The Hedge Fund company now holds 8,330 shares of JNJ which is valued at $917,799. Johnson & Johnson makes up approx 0.60% of E&g Advisors Lp’s portfolio.Prospera Financial Services Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 451 additional shares and now holds a total of 13,906 shares of Johnson & Johnson which is valued at $1,532,163. Johnson & Johnson makes up approx 0.34% of Prospera Financial Services Inc’s portfolio.Peachtree Investment Advisors boosted its stake in JNJ in the latest quarter, The investment management firm added 562 additional shares and now holds a total of 22,178 shares of Johnson & Johnson which is valued at $2,443,572. Johnson & Johnson makes up approx 2.42% of Peachtree Investment Advisors’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.